VISCHER ADVISED RLF IN CLOSING AGREEMENT WITH SONNET BIOTHERAPEUTICS

Posted on 7 April 2020



Category: <u>Deal & transactions</u> Tags: <u>Damien Conus</u>, <u>Ex-Featured</u>, <u>Relief Therapeutics Holding</u>, <u>Sonnet BioTherapeutics</u>, <u>Vischer</u>



Relief Therapeutics Holding (RLF) <u>announces</u> the closing of the binding Share Exchange Agreement for the acquisition by **Sonnet BioTherapeutics**, now a subsidiary of Sonnet BioTherapeutics Holdings (formerly known as Chanticleer Holdings) of Relief Therapeutics, a subsidiary of Relief Holding, signed August 12, 2019. As a consequence, Sonnet acquires all outstanding shares of Relief SA that becomes a wholly owned Geneva-based subsidiary of Sonnet. In counterpart, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock.

Vischer <u>advises</u> the selling shareholder in this transaction. The team was led by partner Damien Conus (head of Geneva m&a/start-up desks).